To include your compound in the COVID-19 Resource Center, submit it here.

Spark gets FDA's first in vivo gene therapy approval

In its first approval of an in vivo gene therapy, FDA approved Luxturna voretigene neparvovec from Spark Therapeutics Inc. (NASDAQ:ONCE) to

Read the full 214 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE